Trials / Completed
CompletedNCT00002315
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
A Double-Blind, Multicenter Study Comparing Oral 882C87 With Oral Acyclovir for Treatment of Localized Herpes Zoster in Immunocompromised Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
Detailed description
Patients are randomized to receive either 882C87 or acyclovir with corresponding placebos for 14 days, with two hundred patients in each of the two groups. They are stratified by presence or absence of HIV infection. Patients undergo 6 months of follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Netivudine | |
| DRUG | Acyclovir |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002315. Inclusion in this directory is not an endorsement.